肥胖、代谢性疾病与胰腺:胰腺脂肪的定量影像学
本文综述非酒精性脂肪性胰腺病的病理生理及其与代谢因素、肥胖和糖尿病的关联,探讨超声、CT和MRI定量胰腺脂肪的方法,评述各方法的优势、局限与现有证据,并讨论将这些方法转化至临床所面临的挑战。
要点
- 超声、CT和MRI均可用于胰腺脂肪定量,但各有优势与局限。
- 定量影像生物标志物可为病理生理研究及新疗法试验提供终点。
- 胰腺脂肪定量方法向临床转化仍面临更广泛的挑战。
核心结论
- 胰腺脂肪与肥胖、代谢疾病的关联已充分记录,但仍知之甚少。
- 无创定量影像生物标志物可提供病理生理见解,并可能为新疗法开发提供稳健的试验终点。
研究设计与样本
- 综述,检索范围与纳入文献原文未报告。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The association between pancreatic fat, obesity and metabolic disease is well-documented, and although a potentially exciting target for novel therapies, remains poorly understood. Non-invasive quantitative imaging-derived biomarkers can provide insights into pathophysiology and potentially provide robust trial endpoints for development of new treatments. In this review, we provide an overview of the pathophysiology of non-alcoholic fatty pancreas disease and associations with metabolic factors, obesity and diabetes. We then explore approaches to pancreatic fat quantification using ultrasound, CT and MRI, reviewing the strengths, limitations and current published evidence in the assessment of pancreatic fat. Finally, we explore the broader challenges of pancreatic fat quantification as we move toward translating these methods into the clinical setting.
引用
- Sakai NS, Taylor SA, Chouhan MD, et al. Obesity, metabolic disease and the pancreas-Quantitative imaging of pancreatic fat. Br J Radiol. 2018. PMID: 29869917. doi:10.1259/bjr.20180267
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。